San Diego, CA, Oct.11, 2013 - Concortis Biosystems, a leader in ADC technology and a global service provider announced that David Miao, Founder and CSO will present at the World ADC Summit Conference in San Francisco, on October 16.
Dr. Miao, Concortis founder and CSO will speak about selective conjugation technologies and will discuss the advantages of the K-LockTM and C-LockTM and their use in generating antibody-drug conjugates with superior profiles. In addition he will present results indicating that Concortis’s conjugation technologies open new avenues to advance conventional ADC-1x to multifunctional ADC-2x, including the precise stoichiometric conjugation of an antibody with two different drug payloads.
About Concortis Biosystems Corp.
Privately held Concortis Biosystems is a leader in ADC technologies with commanding expertise in payloads and linkers as well as in-depth know -how in conjugation technology. Our state of the art R&D facility is located in the heart of Biotech Beach, San Diego and currently houses a staff of 12 scientists, nine of them are senior PhD scientists with averaging more than 10 years in antibody research and bio-conjugation chemistry. Since 2011 Concortis has entered into a number of research collaborations to empower antibodies with the optimal combinations of payloads and conjugation methods. Our profound knowledge of ADC has made us the partner of choice for creating ADC.
Help employers find you! Check out all the jobs and post your resume.
